0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

CHRONIC ARSENICAL POISONING DURING THE TREATMENT OF CHRONIC MYELOID LEUKEMIA

E. V. KANDEL, M.D.; G. V. LEROY, M.D.
Arch Intern Med (Chic). 1937;60(5):846-866. doi:10.1001/archinte.1937.00180050113008.
Text Size: A A A
Published online

The value of inorganic arsenical preparations in the treatment of chronic myeloid leukemia was neglected in the American medical literature from the time that roentgen therapy was suggested by Nicholas Senn1 until the report of Forkner and Scott2 in 1931. The 1931 report described a favorable reaction in nine of ten patients receiving solution of potassium arsenite in subtoxic amounts. Later Forkner3 described its successful use in eighteen patients, none of whom had received the drug for longer than one year. In 1936 Stephens and Lawrence4 reported on seven patients treated successfully for about four years or less. The early authors encountered no complications more serious than transient conjunctivitis, coryza, nausea and diarrhea. One patient had herpes zoster while taking arsenic, but the authors considered that this was as likely to be a feature of the leukemia as a result of the treatment. One of the

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();